What it's for (Indications)
- Flunarizine is primarily indicated for the prophylaxis of migraine, particularly in patients who do not respond to or tolerate other prophylactic treatments.
- It is recognized for its effectiveness in reducing the frequency and severity of migraine attacks, thereby improving the quality of life for individuals suffering from chronic or severe migraine.
- Additionally, flunarizine is used for the symptomatic treatment of vestibular vertigo, stemming from functional disorders of the vestibular system.
- This includes conditions such as Ménière's disease and other forms of vertigo related to disturbances in balance and equilibrium.
- The use of flunarizine for these indications is typically considered after a thorough diagnostic evaluation to rule out other underlying causes and when the potential benefits are deemed to outweigh the risks associated with its adverse effect profile, especially the neurological and psychiatric concerns.
- Its role in these therapeutic areas is well-established in many international guidelines.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical adult dosage for flunarizine, especially for migraine prophylaxis, usually commences with an evening dose of 5 mg. This initial dose may be maintained or, if tolerated and clinically indicated, increased to 10 mg daily, typically administered once daily at bedtime to minimize daytime sedation. Treatment should always be initiated with the lowest effective dose. For the symptomatic treatment of vertigo, similar dosing regimens are often employed, with careful consideration of individual patient response and tolerability. It is generally recommended to use flunarizine for a limited duration, often not exceeding 6 months, and to periodically assess the need for continued treatment based on efficacy and the emergence of adverse effects. Dosage adjustments may be necessary in elderly patients or those with hepatic impairment due to altered pharmacokinetics and increased sensitivity to adverse reactions. Abrupt discontinuation of flunarizine is generally not advised, and a gradual tapering schedule may be considered to avoid potential withdrawal effects or recurrence of symptoms, particularly after prolonged use. |
Safety & Warnings
Common Side Effects
- Flunarizine therapy is associated with a range of adverse effects, some of which can be significant and require careful monitoring.
- The most frequently reported side effects include drowsiness or somnolence, often experienced shortly after initiation of treatment, and substantial weight gain, which can be a dose-limiting factor for some patients.
- Other common adverse reactions include fatigue, asthenia, and gastrointestinal disturbances such as nausea, heartburn, or stomach discomfort.
- More concerning side effects, which are detailed in the 'Serious Warnings' section, involve the central nervous system and psychiatric domain.
- These include the potential development or exacerbation of depressive symptoms and the emergence of extrapyramidal symptoms, such as parkinsonism, akathisia, and dyskinesia.
- Less common side effects can include insomnia, anxiety, dry mouth, muscle aches, and skin reactions like rash or pruritus.
- Patients should be thoroughly counseled on these potential effects and advised to report any new or worsening symptoms to their healthcare provider immediately.
Serious Warnings
- Black Box Warning: SERIOUS WARNINGS: Flunarizine therapy is associated with a significant risk of severe neurological and psychiatric adverse effects that necessitate careful patient selection and diligent monitoring throughout the course of treatment. Foremost among these is the potential for inducing or exacerbating depressive symptoms, particularly in patients with a prior history of depression or other psychiatric conditions. Healthcare professionals should thoroughly assess patients for depressive risk factors before initiating treatment and counsel them on monitoring for mood changes, irritability, or anhedonia. Should depressive symptoms develop or worsen during treatment, immediate discontinuation of flunarizine is warranted, and appropriate psychiatric intervention should be sought. Furthermore, flunarizine carries a considerable risk of extrapyramidal symptoms, including drug-induced parkinsonism (tremor, rigidity, bradykinesia), akathisia, and tardive dyskinesia. This risk is amplified in elderly patients or those with a family history or predisposition to movement disorders. These symptoms can be insidious in onset and may become irreversible if not recognized and managed promptly. Patients must be closely monitored for any signs of abnormal movements, rigidity, tremor, or gait disturbances. If extrapyramidal symptoms manifest, flunarizine should be discontinued immediately. Persistent or increasing fatigue, another common side effect, should also prompt re-evaluation as it may precede more severe adverse reactions. The clinical benefits must be carefully weighed against these significant and potentially irreversible risks for each individual patient, and discontinuation should be considered if no clear benefit is observed after a reasonable trial period.
- Beyond the critical 'Serious Warnings' concerning depression and extrapyramidal symptoms, several other important precautions should be considered when prescribing flunarizine.
- Patients should be advised about the potential for sedation, which can impair their ability to perform tasks requiring mental alertness, such as driving or operating heavy machinery.
- Concomitant use of alcohol or other CNS depressants may augment this sedative effect and should be approached with extreme caution or avoided.
- Due to the risk of significant weight gain, patients should be counselled on lifestyle modifications, including diet and exercise, and monitored regularly for changes in body mass index.
- Although less common, flunarizine has been reported to cause symptoms resembling systemic lupus erythematosus in some rare cases, warranting vigilance for such manifestations.
- It should be used with caution in patients with hepatic impairment, as its metabolism is primarily hepatic, necessitating potential dose adjustments and closer monitoring for drug accumulation.
- Regular clinical assessments are crucial to monitor for adverse effects, evaluate the ongoing efficacy, and determine the necessity of continued treatment.
- Discontinuation should be considered if no significant improvement is observed after a defined treatment period, typically 2-3 months for migraine prophylaxis, or if intolerable side effects emerge.
How it Works (Mechanism of Action)
Flunarizine is a selective calcium entry blocker, primarily targeting the L-type voltage-gated calcium channels located in vascular smooth muscle cells and neuronal cells. Unlike many other calcium channel blockers, it exhibits a high degree of selectivity for cerebral and peripheral vascular beds, with minimal clinically significant effects on myocardial contractility or heart rate at therapeutic doses. Its principal mechanism involves preventing excessive intracellular calcium influx, which is believed to play a crucial role in various pathological processes, including cerebral vasospasm, neuronal hyperexcitability, and ischemic damage, all of which are particularly relevant in the pathogenesis of migraine. By stabilizing neuronal membranes and inhibiting the entry of calcium, flunarizine reduces the frequency of depolarization and limits the spread of cortical spreading depression, a phenomenon implicated in migraine aura and pain. It also possesses properties that improve red blood cell deformability and reduce blood viscosity, contributing to improved microcirculation. Additionally, flunarizine has mild antihistaminic (H1-receptor antagonism) and sedative effects, which may contribute to its overall therapeutic actions and influence its side effect profile.